Objective
To identify immunological correlates of protection from HIV infection and/or progression to AIDS using comparative investigations in human and available relevant NHP systems.
Effective vaccination and/or therapeutic intervention to prevent the spread and development of AIDS is likely to require insight into mechanisms of immunological protection from infection and/or disease. Examples of protection from HIV-1 infection are emerging from different clinical as well as preclinical research settings. Vaccine induced protection against HIV-I infection has been demonstrated in chimpanzees, and in the SIV/macaque model. High-risk, exposed humans who remain virus negative appear to have HIV-1 specific cellular immune responses. With respect to disease, progression to AIDS appears to be inhibited in long-term, infected human survivors, and there is a natural resistance to the development of AIDS in infected chimpanzees and in other lentivirus infected African non human primates. Our studies of host-virus relationships may be divided into investigations of (I) - protection from infection (e.g. due to vaccination or repeated low dose exposure); and (II) - protection from disease progression (due to vaccination. immune modulation or natural resistance of the host).
I) Infection:
a) Vaccine efficacy trials
-(HIV-I vaccine immunogenicity studies in humans and in chimpanzees in the developed and developing world)
b) Multiple exposure/resistance to infection
- in humans chimpanzees and macaques
II) Disease progression
a) Long term asymptomatics (Natural resistance)
- humans infected with HIV-I and HIV-2
- Chimpanzees infected with HIV-l
- African green monkey infected with SIV
b) Acquired resistance to disease
- immunotherapy / post-exposure vaccination
- infection with attenuated viruses
The specific immune mechanisms to be compared include humoral (neutralising antibodies, lg. isotopes. DACCA) and cellular (Th., NK, CTL) arms of the immune system along with their interactions, as well as the influence of host Major Histocompatibility Complex (MHC) polymorphism's on the immune response. The ultimate goal is to bridge the species barrier between preclinical (NHP) and clinical (human) responses to HIV and to identify immunological mechanisms important for protective immunity. This information will assist the development and evaluation of effective vaccines and therapeutic strategies for the prevention of AIDS.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences zoology mammalogy primatology
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
SW10 9NH London
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.